Compounds for therapeutic use

Inventors

Gomez, Laurent • Massari, Mark Eben

Assignees

Dart Neuroscience LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10738018-B2

Patent

Publication Date

2020-08-11

Expiration Date


Abstract

Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

Core Innovation

The invention relates to methods of treating major depressive disorder or persistent depressive disorder by administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I) is defined by a substituted 2-oxa-4-azabicyclo[3.3.1]non-3-en-9-one bicyclic framework bearing a substituted aryl group, including a 2-chlorophenyl group in specific examples, with extensive substituent definitions and stereochemical forms.

The compound definitions encompass multiple structural classes within Formula (I), including substituted carbon-based groups, alkenyl or alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, and acyl, amide, guanidino, amino-hydroxycarbonyl, halogen, hydroxy, alkyl, alkoxy, amino, and carboxyl-related groups. The framework can further incorporate ring-forming options through R9 and R10, with structural constraints for R5 and R6 and for R11 and R12.

The disclosed therapeutic concept is additionally narrowed to specified substituted derivatives within the Formula (I) family, including multiple enumerated (1R,5R) and (1S,5S) stereochemistries and side-chain variants such as aminoalkyl, hydroxyalkyl, methoxyalkyl, heteroaryl-substituted alkyl, and carboxylic acid or amide-related variants. The compounds are framed as alternatives to ketamine and are described in relation to HNK (hydroxynorketamine)-mediated pathways and receptor-related activity in the HNK-mediated pathway.

Claims Coverage

The independent claims are directed to treating major depressive disorder or persistent depressive disorder by administering a therapeutically effective amount of a Formula (I) compound, or a pharmaceutically acceptable salt, and include both a broad substituent-variable framework and an enumerated subset of specific chirally defined derivatives. The main inventive features are centered on the defined Formula (I) structure and its therapeutic use for depression.

Treatment with formula (i) compounds

A method of treating a major depressive disorder or persistent depressive disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, of Formula (I) with extensive substituent options for R1 through R12, including selected alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, carbonyl-related, halogen, hydroxy, amino, and carboxy-related groups.

Treatment with enumerated substituted derivatives

A method of treating a major depressive disorder or persistent depressive disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of specified substituted (1R,5R) and (1S,5S) 2-oxa-4-azabicyclo[3.3.1]non-3-en-9-one derivatives and pharmaceutically acceptable salts thereof.

Claim coverage centers on patient treatment for major depressive disorder or persistent depressive disorder using substituted 2-oxa-4-azabicyclo[3.3.1]non-3-en-9-one Formula (I) compounds, either via broad substituent-variable definitions or via an enumerated subset of specific substituted derivatives. Dependent claims further refine the substituent set and require remission measured on a depression symptoms rating scale.

Stated Advantages

Treat depression by acting through HNK (hydroxynorketamine)-mediated pathways.

Potentially avoid drawbacks associated with ketamine.

In dependent claims, the therapeutically effective amount is sufficient to achieve remission of depression symptoms as measured on a depression symptoms rating scale.

Documented Applications

Treatment of major depressive disorder and persistent depressive disorder.

Treatment of depression using a therapeutically effective amount sufficient to achieve remission measured on a depression symptoms rating scale.

Treatment of pain.

Treatment of dementia/cognitive impairment.

Treatment of neurodegenerative disorders.

Treating major depressive disorder or persistent depressive disorder by administering compounds of Formula (I) or selected enumerated substituted 2-oxa-4-azabicyclo[3.3.1]non-3-en-9-one derivatives to a patient in need thereof.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.